, also known as iron salts
and iron pills
, are a number of iron
formulations used to treat and prevent iron deficiency
including iron deficiency anemia
. For prevention they are only recommended in those with poor absorption
, heavy menstrual periods
, or a diet low in iron. Prevention may also be used in low birth weight
babies. They are taken by mouth, injection into a vein
, or injection into a muscle
. While benefits may be seen in days up to two months may be required until iron levels return to normal.
Common side effects include constipation
, abdominal pain, dark stools, and diarrhea
. Other side effects, which may occur with excessive use, include iron overload
and iron toxicity
. Ferrous salts used as supplements by mouth include ferrous fumarate
, ferrous gluconate
, ferrous succinate
, and ferrous sulfate
. Injectable forms include iron dextran
and iron sucrose
. They work by providing the iron needed for making red blood cells
Iron has been used medically since at least 1681 with an easy to use formulation being created in 1832. It is on the World Health Organization's List of Essential Medicines
, the most effective and safe medicines needed in a health system
. Ferrous salts are available as a generic medication
and over the counter
. The wholesale cost in the developing world
is about 0.05 to 0.63 USD per month. In the United States a typical month of treatment costs less than 25 USD. Slow release
formulations, while available, are not recommended.
Iron supplements are used to treat iron deficiency
and iron-deficiency anemia
; Ferinject (ferric n 2012-12-21.
parenteral irons can also be used to treat functional iron deficiency, where requirements for iron are greater than the body's ability to supply iron such as in inflammatory states. The main criterion is that other causes of anemia have also been investigated, such as vitamin B12/ folate
deficiency, drug induced or due to other poisons such as lead, as often the anaemia has more than one underlying cause.
Iron deficiency anemia is classically a microcytic, hypochromic anemia. Generally, in the UK oral preparations are trialled before using parenteral delivery.Goddard AF, James MW, McIntyre AS and Scott BB (May 2005). Guidelines for the management of iron deficiency anaemia
. British Society of Gastroenterology unless there is the requirement for a rapid response, previous intolerance to oral iron or likely failure to respond. Intravenous iron may decrease the need for blood transfusions
however increases the risk of infections when compared to oral iron. A 2015 Cochrane Collaboration
review found that daily oral supplementation of iron during pregnancy reduces the risk of maternal anaemia and that effects on infant and on other maternal outcomes are not clear. Another review found that "intermittent regimens (of oral iron supplementation) produced similar maternal and infant outcomes as daily supplementation but were associated with fewer side effects". The quality of evidence was poor, though.
There is debate about whether athletes are at an increased risk for iron deficiencies, and whether athletes with low iron, who are not anemic, would benefit from iron supplementation.
Despite these additional sources of iron loss, male athletes have normally been observed to receive adequate amounts of dietary iron at the same levels recommended for the average male. Female athletes, however, have been observed to receive an inadequate supply of iron, but this may be caused more from blood loss from menstruation than from athletic activity. Additionally, pseudoanemia
can be observed in athletes with adequate haemoglobin due to an increase in blood plasma in athletes that dilutes their haemoglobin concentration, making it appear as if they are anemic when they actually have an adequate amount of total haemoglobin.
When an athlete should be recommended to take iron supplements is debated, and should generally be judged on an individual basis. While iron supplementation can be a pragmatic treatment for athletes that are anemic, its effects remain unclear in athletes that are nonanemic. Iron supplementation has not been demonstrated to improve athletic performance in individuals who are nonanemic. For athletes who are nonanemic, however, iron supplementation may function to stave off iron-deficient anemia, as well as prevent excess absorption of toxic metal ions of lead
. Due to risks associated with differing individual tolerances, drug interactions
, and overdosing
, iron supplementation should be directed by a medical professional based off a clinical assessment of the athlete’s iron parameters and not undertaken as self-medication.
Side effects of therapy with oral iron are most often diarrhea
abdominal discomfort. Taken after a meal, side effects decrease, but there is an increased risk of interaction with other substances. Side effects are dose-dependent
, and the dose may be adjusted.
The patient may notice that his/her stools become black. This is completely harmless, but patients must be warned about this to avoid unnecessary concern. When iron supplements are given in a liquid form, teeth may reversibly discolor (this can be avoided through the use of a straw). Intramuscular injection can be painful, and brown discoloration may be noticed.
Treatments with iron(II) sulfate
have higher incidence of adverse events than iron(III)-hydroxide polymaltose complex (IPC) or iron bis-glycinate chelate.
Iron overdose has been one of the leading causes of death caused by toxicological agents in children younger than 6 years.
Iron poisoning may result in mortality or short-term and long-term morbidity. Toxicity, Iron (Overview)
. Tripdatabase.com. Retrieved on 2012-12-21.
Because one of the functions of elevated ferritin
(an acute phase reaction protein) in acute infections is thought to be to sequester iron from bacteria, it is generally thought that iron supplementation (which circumvents this mechanism) should be avoided in patients who have active bacterial infections. Replacement of iron stores is seldom such an emergency situation that it cannot wait for any such acute infection to be treated.
Some studies have found that iron supplementation can lead to an increase in infectious disease
morbidity in areas where bacterial infections are common. For example, children receiving iron-enriched foods have demonstrated an increased rate in diarrhea
overall and enteropathogen shedding. Iron deficiency protects against infection by creating an unfavorable environment for bacterial growth. Nevertheless, while iron deficiency might lessen infections by certain pathogenic diseases, it also leads to a reduction in resistance to other strains of viral or bacterial infections, such as Salmonella typhimurium
or Entamoeba histolytica
. Overall, it is sometimes difficult to decide whether iron supplementation will be beneficial or harmful to an individual in an environment that is prone to many infectious diseases; however this is a different question than the question of supplementation in individuals who are already ill with a bacterial infection.
Children living in areas prone for malarial infections are also at risk of developing anemia. It was thought that iron supplementation given to such children could increase the risk of malarial infection in them. A Cochrane systematic review published in 2016 found high quality evidence that iron supplementation does not increase the risk of clinical malaria in children.
Contraindications often depend on the substance in question. Documented hypersensitivity
to any ingredients and anemias without proper work-up (i.e., documentation of iron deficiency) is true of all preparations. Some can be used in iron deficiency, others require iron deficiency anaemia to be present. Some are also contraindicated in rheumatoid arthritis CosmoFer – Summary of Product Characteristics (SPC) – (eMC)
. Medicines.org.uk. Retrieved on 2012-12-21.
Individuals may be genetically predisposed to excessive iron absorption, as is the case with those with HFE hereditary haemochromatosis
. Within the general population, 1 out of 400 people has the homozygous form of this genetic trait, and 1 out of every 10 people has its heterozygous form. Neither individuals with the homozygous or heterozygous form should take iron supplements.
iron forms an insoluble complex with several other drugs, resulting in decreased absorption of both iron and the other drug. Examples include tetracycline
. The same can occur with elements in food, such as calcium
. Absorption of iron is better at a low pH (i.e. an acidic environment), and absorption is decreased if there is a simultaneous intake of antacids.
Many other substances decrease the rate of non-heme iron absorption. Examples are tannins
from foods, such as tea
and saw palmetto
, phytic acid and roughage. Boosting iron absorption: A guide to for the science-minded
. Parentingscience.com. Retrieved on 2012-12-21. Vegetarians and especially vegans are at increased risk of iron deficiency
due to the combination of limited amounts of iron in the diet in a form that is poorly absorbed alongside compounds that further limit absorption.
Taken after a meal, there are fewer side effects but there is also less absorption because of interaction and pH alteration. Generally, an interval of 2–3 hours between the iron intake and that of other drugs seems advisable, but is less convenient for patients and can impact on compliance.
The first pills were commonly known as Blaud's pills, Blaud's pill – Medical Definition and More from
. Merriam-Webster. Retrieved on 2012-12-21. which were named after P. Blaud of Beaucaire
, the French physician who introduced and started the use of these medications as a treatment for patients with anemia
., p. 435.
Iron can be supplemented by mouth
using various forms, such as iron(II) sulfate
. This is the most common and well studied soluble iron salt
sold under brand names such as Feratab, Fer-Iron, and Slow-FE. It is in complex with gluconate
, carbonyl iron
, and other salts. Ascorbic acid
, vitamin C, increases the absorption of non-heme sources of iron.
Heme iron polypeptide (HIP) (e.g. Proferrin ES and Proferrin Forte) can be used when regular iron supplements such as ferrous sulfate or ferrous fumarate are not tolerated or absorbed. A clinical study demonstrated that HIP increased serum iron levels 23 times greater than ferrous fumarate on a milligram-per-milligram basis.
Another alternative is ferrous glycine sulfate
or ferroglycine sulfate
, has less gastrointestinal side-effects than standard preparations such as iron fumarate. It is unusual among oral preparations of iron supplements in that the iron in this preparation has very high oral bioavailability, especially in the liquid formulation. This option should be evaluated before resorting to parenteral therapy. It is especially useful in iron deficiency anemia associated with autoimmune gastritis
and Helicobacter pylori
gastritis, where it generally has satisfactory effect.
Since iron stores in the body are generally depleted, and there is a limit to what the body can process (about 2–6 mg/kg of body mass per day; i.e. for a 100 kg/220 lb man this is equal to a maximum dose of 200–600 mg/per day) without iron poisoning
, this is a chronic therapy which may take 3–6 months. Iron Poisoning
. Webmd.com (2012-09-27). Retrieved on 2012-12-21.
Due to the frequent intolerance of oral iron and the slow improvement, parenteral iron is recommended in many indications.
Iron therapy (intravenously or intramuscular) is given when therapy by mouth has failed (not tolerated by the patient), oral absorption is seriously compromised (by illnesses, or when the patient cannot swallow), benefit from oral therapy cannot be expected, or fast improvement is required (for example, prior to elective surgery). Parenteral therapy is more expensive than oral iron preparations and is not suitable during the first trimester of pregnancy
There are cases where parenteral iron is preferable over oral iron. These are cases where oral iron is not tolerated, where the haemoglobin
needs to be increased quickly (e.g. post partum, post operatively, post transfusion), where there is an underlying inflammatory condition (e.g. inflammatory bowel disease) or renal patients, the benefits of parenteral iron far outweigh the risks. In many cases, use of intravenous iron such as ferric carboxymaltose
has lower risks of adverse events than a blood transfusion and as long as the person is stable is a better alternative. Ultimately this always remains a clinical decision based on local guidelines, although National Guidelines are increasingly stipulating IV iron in certain groups of patients.
Soluble iron salts have a significant risk of adverse effects and can cause toxicity due to damage to cellular macromolecules. Delivering iron parenterally has utilised various different molecules to limit this. This has included dextrans
, carboxymaltose and more recently Isomaltoside 1000.
One formulation of parenteral iron is iron dextran
which covers the old high molecular weight (trade name DexFerrum
) and the much safer low molecular iron dextrans (tradenames including Cosmofer and Infed).
(trade names including Venofer
) has an occurrence of allergic reactions of less than 1 in 1000. Venofer
in FASS (drug formulary)
, translated from Swedish "Allergiska reaktioner (inträffar hos färre än 1 av 1 000 patienter)" and "Vanliga (inträffar hos färre än 1 av 10 patienter): Tillfälliga smakförändringar (speciellt metallsmak)." A common side effect is taste changes, especially a metallic taste
, occurring in between 1 in 10 and 1 in 100 treated patients. It has a maximum dose of 200 mg on each occasion according to the SPC, but it has been given in doses of 500 mg. Doses can be given up to 3 times a week
is marketed as Ferinject
, and Iropremand
in various countries. The most common side effects are headaches
which occur in 3.3 %, and hypophosphatemia, which occurs in more than 35 %. Ferinject (ferric carboxymaltose) – Summary of Product Characteristics (SPC) – (eMC)
. Medicines.org.uk. Retrieved on 2012-12-21. See FDA index page for NDA 203565
for updates and further information.
Iron Isomaltoside 1000
(Trade name Monofer
) is a newer formulation of parenteral iron that has a matrix structure that results in very low levels of free iron and labile iron. It can be given at high doses – 20 mg/kg in a single visit – no upper dose limit. This formulation has the benefit of giving a full iron correction in a single visit.
Follow-up is needed to ensure compliance and to detect adequate response to therapy. The interval of follow up can widely depend on both the method of administration, and the underlying pathology. For parenteral irons it is recommended that there be a period of 4 weeks before repeating blood test to allow the body to utilise the iron. For oral iron, this can take considerably longer, so waiting 3 months may be appropriate.